Heron Therapeutics, Inc. (HRTX) Stock Overview
Explore Heron Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Heron Therapeutics, Inc. (HRTX)
Key Financials
Key Financials
Market Cap
56.6M
P/E Ratio
-1.62
EPS (TTM)
$-0.13
ROE
-3.01%
HRTX Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Heron Therapeutics, Inc. (NASDAQ: HRTX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Heron Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of HRTX on the NASDAQ shows an RSI of 39.38, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $0.37 for the NASDAQ listing.
Key metrics behind Heron Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -1.62 and a market capitalization of 56.6M. Combined with our AI analysis, these give both institutional and retail investors a clear view of HRTX on the NASDAQ.